ArticleBMC public health2026
"Why should I pay for this vaccine?" - Norwegian adolescents views on meningococcal vaccination.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs one of few countries in Europe, Norway does not offer vaccination against invasive meningococcal disease (IMD) as part of the National Immunization Program for Children (NIP). Instead, adolescents aged 16-19 are recommended to consider having the meningococcal ACWY conjugate vaccine (MCV4) if they participate in activities that increase the risk of IMD. Meningococcal vaccination rates in Norway are low compared to vaccines offered through the NIP. Whereas all vaccinations in the NIP are free and organized through schools or municipal health clinics, there is no uniform system in place for the meningococcal vaccine. On the contrary, both administration practices and cost of vaccination vary nationally, with some counties offering the vaccine for free, while others offer the vaccine at a cost of $40-80. The aim of this study was to explore adolescents' awareness, knowledge, and decision-making processes related to meningococcal disease and vaccination.
methodsUsing a semi-structured interview guide, we conducted 18 focus group interviews in the fall of 2022, involving a total of 126 high school seniors in Norway. The participants were asked to share their views, knowledge and experiences regarding invasive meningococcal disease and vaccination. We used NVivo 14 to facilitate the thematic analysis and a codebook analysis approach was conducted to identify themes and patterns in the data.
resultsThe analysis identified three central themes emerging from the discussions with the adolescents. These emphasize how information, cost, and location and guidance impact the adolescents' decision-making and ability to get vaccinated.
conclusionsThe current organization of MCV4 vaccination in Norway do not meet the needs identified by the adolescents in this study. This results in unequal access to a highly effective vaccine that protects healthy adolescents against a deadly disease. The present study highlights the need to address vaccination disparities and accessibility, as well as increasing awareness and knowledge about meningococcal disease and vaccination to ensure equal access for all adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.